

# CONTENTS

---

Preface .....	v
Contributors .....	ix
 PART I. GENERAL/BACKGROUND .....	 1
1 Chemoradiation: <i>Biological Principles and Perspectives</i> .....	3
<i>Hak Choy and Robert M. MacRae</i>	
2 Fluoropyrimidines as Radiation Sensitizers .....	23
<i>Muhammad Wasif Saif and Robert B. Diasio</i>	
 PART II. MECHANISMS OF INTERACTION OF SPECIFIC CHEMOTHERAPEUTIC AGENTS WITH RADIATION .....	 45
3 The Role of Platinum Complexes in Combined Modality Therapy .....	47
<i>Beverly A. Teicher</i>	
4 Taxanes in Combined Modality Therapy .....	65
<i>Robert M. MacRae and Hak Choy</i>	
5 Camptothecin Radiation Sensitization .....	93
<i>Tyvin A. Rich</i>	
6 The Role of Gemcitabine in Combined Modality Therapy .....	105
<i>Jerome Landry, William Blackstock, Robert M. MacRae,         Gary Yang, and Hak Choy</i>	
 PART III. CLINICAL APPLICATIONS .....	 127
7 Chemoradiation Strategies for Patients with Malignant Gliomas .....	129
<i>Heather A. Curry and Walter J. Curran, Jr.</i>	
8 Combined Modality Strategies in the Treatment of Head and Neck Cancer .....	145
<i>Cathy Eng and Everett E. Vokes</i>	
9 The Role of Combined Modality Therapy for Stage III Nonsmall-Cell Lung Cancer .....	175
<i>Roger W. Byhardt</i>	
10 Combined Modality Treatment of Small-Cell Lung Cancer .....	197
<i>Julie R. Brahmer, Larry Kleinberg, and David S. Ettinger</i>	

12	Combined Modality Therapy in Locally Advanced Breast Cancer .....	237
	<i>Silvia C. Formenti and Matthew Volm</i>	
13	Combined Modality Therapy for Gastric, Pancreatic, and Biliary Tract Carcinomas .....	253
	<i>Alexandria Phan and Jaffer A. Ajani</i>	
14	Chemoradiation in Therapy for Colon and Rectum Carcinoma .....	271
	<i>Jason H. Lee and Christopher G. Willett</i>	
15	Chemoradiotherapy in Muscle-Invasive Bladder Cancer .....	291
	<i>Bruce J. Roth</i>	
16	The Role of Combined Chemotherapy and Radiation Therapy in the Treatment of Gynecologic Malignancies .....	303
	<i>Patricia J. Eifel</i>	
PART IV. SPECIFIC MOLECULAR TARGETED AGENTS .....		321
17	Overview of Specific Molecular Targeted Agents for Combined Modality Therapy .....	323
	<i>Scott Saxman and Janet Dancey</i>	
18	Receptor Tyrosine Kinases as Therapeutic Targets in Solid Tumors .....	339
	<i>Stacy L. Moulder and Carlos L. Arteaga</i>	
19	Adenoviral p53 Gene Therapy Strategies in Nonsmall-Cell Lung Cancer .....	349
	<i>Stephen G. Swisher and Jack A. Roth</i>	
20	Tumor Microvasculature as a Therapeutic Target During Radiotherapy .....	359
	<i>Dennis E. Hallahan and Don Stacy</i>	
21	Cancer Drug Discovery and Development: <i>Maximizing the Therapeutic Potential of Matrix Metalloproteinase Inhibitors for the Treatment of Cancer</i> .....	379
	<i>Jeffrey S. Humphrey, Karen Price, Elora Gupta, Andrew Baxter, John Bird, Daryl Sonnichsen, and Joseph Naglich</i>	
22	The Role of Cyclooxygenase-2 Inhibitors in Combined Modality Therapy .....	391
	<i>Hong Pyo, Raymond N. DuBois, and Hak Choy</i>	
	Index .....	409



<http://www.springer.com/978-1-58829-028-1>

Chemoradiation in Cancer Therapy

Choy, H. (Ed.)

2003, XII, 420 p., Hardcover

ISBN: 978-1-58829-028-1

A product of Humana Press